Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus brevis is a probiotic bacterium that has been investigated for its potential role in supporting gut health, including inflammatory bowel disorders (IBD) such as Crohn’s disease and ulcerative colitis. The use of L. brevis in IBD is primarily supported by early-stage scientific research, mainly from animal studies and in vitro experiments, with limited clinical trials in humans.

Preclinical studies have shown that L. brevis can modulate immune responses, enhance gut barrier function, and reduce markers of inflammation. For example, animal models of colitis have demonstrated that L. brevis administration can decrease levels of pro-inflammatory cytokines (such as TNF-α and IL-6), increase anti-inflammatory cytokines, and reduce colonic tissue damage. In vitro research suggests that L. brevis can strengthen tight junctions in the intestinal epithelium and inhibit the growth of pathogenic bacteria, potentially contributing to an improved gut environment.

However, direct evidence in humans is sparse. Some small studies have included L. brevis as part of multi-strain probiotic formulations tested in IBD patients, but the results have been mixed and often do not isolate the effects of L. brevis alone. As a result, while there is a scientific rationale for exploring L. brevis in IBD management, the current evidence is insufficient for strong clinical recommendations, and larger, well-controlled human studies are needed.

More about lactobacillus brevis
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by lactobacillus brevis

Products containing lactobacillus brevis

Douglas Laboratories Multi-Probiotic ® 40 Billion
Douglas Laboratories Multi-Probiotic ® 40 Billion